New compounds targeting the pathways critical to cancer and end-organ damage

CCRP Therapeutics is a biopharmaceutical spin-off of Charité's Center for Cardiovascular Research (CCR).

The company's focus is the discovery of renin/ prorenin receptor blockers (RERBs) for multiple oncological indications (colorectal cancer,  hepatocellular carcinoma, pancreatic cancer and sarcoma) as well as for the treatment of end-organ damage caused by diabetes and hypertension.